openPR Logo
Press release

Bacterial Endocarditis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results

04-08-2019 03:36 PM CET | Health & Medicine

Press release from: Pharma Proff

Bacterial Endocarditis Therapeutics - Pipeline Analysis 2018,

Bacterial endocarditis is an infection of inner lining of the valves and heart chamber. This infection can cause serious inflammation in heart and can develop fatal complications.

Download the sample report @ https://www.pharmaproff.com/request-sample/1054

It has been observed that patients who have undergone implantations like heart valve replacement, or have congenital heart defects are more susceptible to this disease. Bacterial endocarditis can be diagnosed by blood tests, echocardiography, and electrocardiogram.

Get the detailed analysis @ https://www.pharmaproff.com/report/bacterial-endocarditis-therapeutics-pipeline-analysis

The treatment procedure for this disease involves the administration of antibiotics, and requires a surgical procedure in severe cases. ContraFect Corporation is in the process of developing CF-301, a bacteriophage-derived lysin, for the treatment of bacterial endocarditis.

Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1054

• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bacterial Endocarditis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results here

News-ID: 1693495 • Views: 338

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for Bacterial

Acute Conjunctivitis Treatment Market | Bacterial conjunctivitis | PBIGP
The Future Insights Of Global Acute Conjunctivitis Treatment Market Conjunctivitis, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Conjunctivitis can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but treatment can
Bacterial Conjunctivitis Drugs Market: Rising Incidence of Ophthalmic Bacterial …
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as
Bacterial Conjunctivitis Drugs Market Driven by Rising Incidence of Ophthalmic B …
The U.S. market for bacterial conjunctivitis drugs is extremely fragmented, leading to commensurate competition among players. The entry barriers faced by new players despite having good research and development capabilities, is lack of capital, Transparency Market Research (TMR) states in its new report on the U.S. market for bacterial conjunctivitis drugs. R&D involves huge costs and this limits the production. Mergers and acquisitions and other forms of strategic alliances can
Bacterial Gastroenteritis Testing Market Future Opportunities 2026
Bacterial gastroenteritis is infection in the gut (gastrointestinal tract). Major bacteria causing gastroenteritis are C. difficile, C. jejuni, shigella, E. coli, and several species of salmonella. These bacteria are usually transmitted by means of ingesting contaminated food or liquids, person-to-person contact, and contact with animals. The diseases caused by these bacteria may be asymptomatic or may have mild to severe symptoms. Some of the common symptoms caused by enteric bacteria
Bacterial Vaginosis Drug Market is Growing Rapidly Due To Rising Awareness About …
Worldwide Market Reports added Latest Research Report titled "Global Bacterial Vaginosis Drug Market by Manufacturers, Regions, Product Type and Application, Forecast to 2022" to its Large Report database. In this report, the global Bacterial Vaginosis Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Ask For Sample Copy
Global Chronic Bacterial Prostatitis Market Research Report
Latest industry research report on: Global Chronic Bacterial Prostatitis Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts GlobalData's clinical trial report, Chronic Bacterial Prostatitis Global Clinical Trials Review, H1, 2017" provides an overview of Chronic Bacterial Prostatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Bacterial Prostatitis. Report includes an overview of trial numbers and their average